Cosmo Bio Co

Cosmo Bio Co Net Debt / EBITDA

The Net Debt to EBITDA of Cosmo Bio Co (3386.T) as of Nov 1, 2026 is -8.56. In the previous year, Net Debt to EBITDA was -8.40 — a change of 1.86% (lower).

Net Debt / EBITDA

-8.56

YoY

1.86%

Last updated:

Net Debt to EBITDA of Cosmo Bio Co is 2025 -8.56 . Net Debt to EBITDA of Cosmo Bio Co was 2024 -8.40 . It decreases by 1.86% lower compared to the previous year.

The Cosmo Bio Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-6.83 JPY
Jan 1, 2019
-6.15 JPY
Jan 1, 2020
-4.31 JPY
Jan 1, 2021
-3.37 JPY
Jan 1, 2022
-3.69 JPY
Jan 1, 2023
-5.78 JPY
Jan 1, 2024
-8.40 JPY
Jan 1, 2025
-8.56 JPY
The Cosmo Bio Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-8.56+1.86%
-8.40+45.26%
-5.78+56.81%
-3.69+9.57%
-3.37-21.86%
-4.31-29.94%
-6.15-10.03%
-6.83-9.39%
-7.54+71.32%
-4.40-40.14%
-7.35-18.02%
-8.97-0.30%
-9.00+169.99%
-3.33+17.34%
-2.84+3.13%
-2.75-47.57%
-5.25+18.23%
-4.44+113.33%
-2.08+173.03%
-0.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Net Debt to EBITDA of Cosmo Bio Co is -8.56 in 2025.

Net Debt to EBITDA of Cosmo Bio Co changed from -8.40 to -8.56, representing a 1.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Cosmo Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co